Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:01:40.550Z.
Calculation as of: 2026-10-06T18:01:40.550Z.
Quote observation: 2026-10-06T18:00:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$629.45M
PS Ratio
154.54
TTM Avg
124.66
3Y Avg
326.25
5Y Avg
326.25
Market Cap
$600.59M
PS Ratio
1.54
TTM Avg
1.87
3Y Avg
2.03
5Y Avg
3.14
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $615.86M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $629.45M | 154.54 | 124.66 | 326.25 | 326.25 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.59M | 1.54 | 1.87 | 2.03 | 3.14 |
| Aura Biosciences, Inc. (AURA)vs › | $634.07M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $634.15M | 7.36 | 4.88 | 4.31 | 6.09 |
| AngioDynamics, Inc. (ANGO)vs › | $596.40M | 1.86 | 1.66 | 1.27 | 1.62 |
| OmniAb, Inc. (OABI)vs › | $638.60M | 16.62 | 10.67 | 12.29 | 15.93 |
| Fulgent Genetics, Inc. (FLGT)vs › | $587.46M | 1.81 | 2.02 | 2.17 | 2.12 |
| OrthoPediatrics Corp. (KIDS)vs › | $586.85M | 2.32 | 1.86 | 2.98 | 5.39 |
| Starling Oncology, Inc. (STLN)vs › | $657.51M | 1.12 | 1.06 | 1.06 | 1.06 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
